Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul M Kaye

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Wellcome Open Research|January 25, 2020
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasisSarah Forrester, Karin Siefert, Helen Ashwin, et al.
Archives of Toxicology|August 18, 2015
Bile canalicular dynamics in hepatocyte sandwich culturesRaymond Reif, Johan Karlsson, Georgia Günther, et al.
ERJ Open Research|December 2, 2020
Azithromycin for sarcoidosis cough: an open-label exploratory clinical trialSimon D Fraser, Susannah Thackray-Nocera, Marica Shepherd, et al.
Nature Communications|July 7, 2017
Skin parasite landscape determines host infectiousness in visceral leishmaniasisJohannes S P Doehl, Zoe Bright, Shoumit Dey, et al.
Plos Pathogens|September 20, 2008
VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasisAmanda C Stanley, Jane E Dalton, Susanna H Rossotti, et al.
The Journal of Infectious Diseases|February 4, 2012
Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasisAsher Maroof, Najmeeyah Brown, Barbara Smith, et al.
Communications Biology|March 21, 2026
Ontogeny independent expression of LPCAT2 in granuloma macrophages during experimental visceral leishmaniasisShoumit Dey, Jian-Hua Cao, Benjamin Balluff, et al.
The Journal of Clinical Investigation|May 15, 2025
IL-32-producing CD8+ memory T cells define immunoregulatory niches in human cutaneous leishmaniasisNidhi S Dey, Shoumit Dey, Naj Brown, et al.
Journal of Clinical Pathology|March 9, 2023
Identification of a protein expression signature distinguishing early from organising diffuse alveolar damage in COVID-19 patientsHelen Ashwin, Luke Milross, Julie Wilson, et al.
Plos Neglected Tropical Diseases|May 13, 2017
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KHMohamed Osman, Anoop Mistry, Ada Keding, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Wellcome Open Research|January 25, 2020
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasisSarah Forrester, Karin Siefert, Helen Ashwin, et al.
Archives of Toxicology|August 18, 2015
Bile canalicular dynamics in hepatocyte sandwich culturesRaymond Reif, Johan Karlsson, Georgia Günther, et al.
ERJ Open Research|December 2, 2020
Azithromycin for sarcoidosis cough: an open-label exploratory clinical trialSimon D Fraser, Susannah Thackray-Nocera, Marica Shepherd, et al.
Nature Communications|July 7, 2017
Skin parasite landscape determines host infectiousness in visceral leishmaniasisJohannes S P Doehl, Zoe Bright, Shoumit Dey, et al.
Plos Pathogens|September 20, 2008
VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasisAmanda C Stanley, Jane E Dalton, Susanna H Rossotti, et al.
The Journal of Infectious Diseases|February 4, 2012
Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasisAsher Maroof, Najmeeyah Brown, Barbara Smith, et al.
Communications Biology|March 21, 2026
Ontogeny independent expression of LPCAT2 in granuloma macrophages during experimental visceral leishmaniasisShoumit Dey, Jian-Hua Cao, Benjamin Balluff, et al.
The Journal of Clinical Investigation|May 15, 2025
IL-32-producing CD8+ memory T cells define immunoregulatory niches in human cutaneous leishmaniasisNidhi S Dey, Shoumit Dey, Naj Brown, et al.
Journal of Clinical Pathology|March 9, 2023
Identification of a protein expression signature distinguishing early from organising diffuse alveolar damage in COVID-19 patientsHelen Ashwin, Luke Milross, Julie Wilson, et al.
Plos Neglected Tropical Diseases|May 13, 2017
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KHMohamed Osman, Anoop Mistry, Ada Keding, et al.
Pageof 14